Physician profile
Muhammad Umer Awan
NPI 1306263736
$3,971.21
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,265 · 2020: $90.51 · 2021: $79.82 · 2022: $32.03 · 2023: $83.32 · 2024: $1,420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $983 · Food and Beverage: $521.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $983.02 |
| Food and Beverage | $520.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $1,984.68 | 2019 | |
| Medtronic, INC. | $1,420.40 | 2024 | Venaseal |
| Abbott Laboratories | $207.42 | 2019-2022 | |
| Amgen INC. | $51.24 | 2019 | |
| Mannkind Corporation | $46.02 | 2023 | Afrezza |
| Novartis Pharmaceuticals Corporation | $43.85 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $35.93 | 2019 | |
| Janssen Pharmaceuticals, INC | $33.48 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $24.90 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $24.75 | 2019 | |
| Alnylam Pharmaceuticals INC. | $21.66 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $17.91 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $16.30 | 2023 | Quviviq |
| Allergan, INC. | $15.65 | 2021 | |
| Pfizer INC. | $14.96 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $12.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Awan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.